Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMBARK Phase 3 Study of SRP-9001 in Duchenne Muscular Dystrophy
2019-003374-91Phase 3Completed
- Sponsor
- Sarepta Therapeutics
- Start
- Sep 2021
- Modality
- Gene Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Duchenne muscular dystrophy (DMD) comparing SRP-9001 with Placebo (2 arms). Primary endpoint: Change in NSAA total score from Baseline to Week 52 (Part 1). Started Sep 2021; status: completed.
02
Drugs
delandistrogene moxeparvovec
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on 2019-003374-91.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003374-91.